CURRENT CLINICAL TRIALS FOR THE MPNs
Source of all information: clinicaltrials.gov

· Trials for Myelofibrosis

· Trials for Polcythemia Vera

· Trials for Essential Thrombocythemia

· Trials for other MPNs

2. Trials for Polcythemia Vera

Line No.	Recruiting Status	Condition(s) to be Studied	Drugs tested and primary outcomes	clinicaltrials.gov ref. # - click it for more information	Study title	Study Phase*
1	Recruiting	High Risk Polycythemia Vera High Risk Essential Thrombocythemia	Drug: PEGASYS Drug: Hydroxyurea Drug: Aspirin To compare hematologic response rates in patients randomized to treatment with Pegylated Interferon Alfa-2a vs Hydroxyurea in two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET).	NCT01259856	Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)	Phase III
2	Recruiting	Polycythemia Vera	Drug: INC424 tablets Other: Best Available Therapy (BAT) Proportion of subjects achieving a response at Week 32. 'Response' is defined as having achieved both: (1) the absence of protocol-defined phlebotomy eligibility and (2) a ≥ 35% reduction from baseline in spleen volume as determined by imaging	NCT01243944	Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: The RESPONSE Trial	Phase III
3	Not yet recruiting	High Risk Polycythemia Vera High Risk Essential Thrombocythemia	Drug: PEGASYS Drug: Aspirin Evaluate the ability of Pegylated Interferon Alfa-2a to achieve Complete Response or Partial Response in patients with (1) high risk polycythemia vera or (2) high risk essential thrombocythemia or (3) splanchnic vein thrombosis	NCT01259817	Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)	Phase II
4	Not yet recruiting	Polycythemia Vera Essential Thrombocythemia Primary Myelofibrosis	Drug: PegIntron Drug: Pegasys Drug: Hydrea Drug: Multiferon molecular response (changes from baseline) Molecular responses (JAK V617F allele burden) are assesed by qPCR according to the ELN guidelines.	NCT01387763	A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms	Phase III
5	Recruiting	Polycythemia Vera	Drug: PEG-P-INF alpha-2b (P1101) Maximum tolerated dose (MTD) The definition of MTD is based on a 3+3 dose escalation design. MTD is defined as the next lower dose of that dose which was considered to be untolerated (observed DLT frequency at least 2 out of 3 in one cohort or at least 2 out of six patients in 2 cohorts).	NCT01193699	Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera	Phase I Phase II
6	Recruiting	Polycythemia Vera Thrombocythemia	Drug: CC-4047 Number of Patients with Response	NCT00946270	Pomalidomide for Myelofibrosis Patients	Phase II
7	Recruiting	Myelofibrosis Primary Myelofibrosis Post-polycythemia Vera Related Myelofibrosis Post-essential Thrombocythemia Related Myelofibrosis	Biological: monoclonal antibody to TGF-beta To assess the safety and tolerability of GC1008 in patients with primary myelofibrosis (PMF) or post-polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF).	NCT01291784	Anti-TGF-beta Therapy in Patients With Myelofibrosis	Phase I
8	Recruiting	Primary Myelofibrosis (MF) Post-Polycythemia Vera (PV) MF Post-Essential Thrombocythemia (ET) MF	Drug: Ruxolitinib Efficacy by reduction in spleen volume	NCT01392443	Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF	Phase II
9	Recruiting	Myeloproliferative Disorders Thrombocythemia, Essential Polycythemia Vera Primary Myelofibrosis	Drug: LY2784544 Determination of a recommended Phase 2 dosing regimen Number of participants with clinical significant effects	NCT01134120	A Study in Myeloproliferative Disorders	Phase I
10	Not yet recruiting	Primary Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis	Drug: AB0024 Using the International Working Group criteria, determine the number of patients that respond to AB0024 ater 2 cycles of treatment. If no patients respond after 2 cycles, the study will be stopped.	NCT01242709	Study in Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis	Phase II
11	Recruiting	Polycythemia Vera	Drug: Erlotinib Overall response rate to include Complete Hematological response, Complete molecular response, partial hematological response, and minimal hematological response	NCT01038856	Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera	Phase II
12	Recruiting	Primary Myelofibrosis Post-Polycythemia Vera Post-Essential Thrombocythemia Myelofibrosis	Drug: CYT387 To determine the safety of CYT387 by characterization and relationship of adverse events, affects on vital signs and laboratory parameters, and QTc intervals as measured by electrocardiogram (ECG) To determine maximum tolerated dose of CYT387 by characterization of Dose Limiting Toxicities To confirm the half-life of CYT387 by pharmacokinetic analyses To determine the efficacy of CYT387 by evaluation of spleen and liver size, disease related constitutional symptoms, transfusion dependence and anemia response.	NCT01423058	Safety Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis	Phase I Phase II
13	Recruiting	Primary Myelofibrosis Post Essential Thrombocythemia-myelofibrosis Post Polycythemia Vera-myelofibrosis	Drug: Ruxolitinib (INCB018424) Measure spleen volume changes in patients with PMF, PPV-MF and PET-MF	NCT01348490	Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis	Phase II
14	Recruiting	Idiopathic Myelofibrosis Post Essential Thrombocythemia Myelofibrosis Post Polycythemia-Vera Myelofibrosis	Drug: panobinostat, ruxolitinib Percentage of Responders as measured by a change in spleen length of at least 50% reduction as determined by manual palpation; from Baseline (Cycle 1 Day 1) to Week 12, and maintained until Week 24	NCT01433445	Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis	Phase I
15	Recruiting	Primary Myelofibrosis Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase	Drug: Ruxolitinib Mean % change in spleen volume as measured by MRI	NCT01445769	Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis	Phase II
16	Recruiting	Hematopoietic Neoplasm	Drug: SAR302503 Polycythemia vera: Proportion of patients with absence of phlebotomy and hematocrit below 45% for a minimum of 3 months after completion of 8 cycles of therapy Essential thrombocythemia: Proportion of patients with a platelet count ≤ 400 x 10x9/L for a minimum of 3 months after completion of 8 cycles of therapy	NCT01420783	Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia	Phase II
17	Recruiting	Primary Myelofibrosis Post-Polycythemia Vera Related Myelofibrosis Post-Essential Thrombocythemia Related Myelofibrosis	Drug: LBH589 To assess the safety and tolerability of oral LBH589 in patients with PMF, post-PV/ET MF Phase I Evaluation of treatment response by International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Phase II	NCT01298934	LBH589 (Panobinostat) for the Treatment of Myelofibrosis	Phase I Phase II
18	Recruiting	Hematopoietic Neoplasm	Drug: SAR302503 Drug: Placebo Response Rate (RR), defined as the proportion of patients who have a ≥35% reduction in volume of spleen size at the end of Cycle 6, and confirmed 4 weeks thereafter	NCT01437787	Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis	Phase III
20	Recruiting	Myelofibrosis	Drug: GS-6624 (AB0024) at 700 mg Drug: GS-6624 (AB0024) at 200 mg Using the International Working Group criteria, determine the number of patients that respond to AB0024 ater 2 cycles of treatment •To evaluate the efficacy of AB0024 as therapy for Primary Myelofibrosis (PMF) and Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (post-PV MF or post-ET MF). Best overall response will be categorized according to the International Working Group (IWG) Criteria. Efficacy will be measured by Rate of clinical response as defined by IWG criteria. Stable disease with improvement in bone marrow fibrosis score, clinical improvement, partial remission, or complete remission will be considered a response.	NCT01369498	A Phase 2 Study to Evaluate the Efficacy and Safety of AB0024 in Adults With Myelofibrosis	Phase II
21	Recruiting	Hematopoietic Neoplasm	Drug: SAR302503 The percent change in spleen volume based on MRI at the end of Cycle 3 relative to baseline	NCT01420770	Phase 2 Study of SAR302503 in Patients With Myelofibrosis	Phase II
22	Recruiting	Myelofibrosis	Drug: Ruxolitinib To establish the MSSD of ruxolitinib in patients with MF and baseline platelet counts < 100,000 as measured through blood sampling.	NCT01317875	Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)	Phase I
23	Recruiting	Myelofibrosis	Drug: Busulfan Drug: Fludarabine Drug: Thymoglobulin (ATG) Rate of Non-Relapse Mortality (NRM)	NCT00475020	Allogeneic Stem Cell Transplantation for Myelofibrosis	Phase II
24	Recruiting	Myeloproliferative Diseases	Drug: Ruxolitinib Drug: Lenalidomide Drug: Prednisone Objective Response Rate Objective response rate equals Complete and Partial Response, and Clinical Improvement as defined by International Working Group for Myelofibrosis Research and Treatment (IWG-MRT).	NCT01375140	Ruxolitinib and Lenalidomide for Patients With Myelofibrosis	Phase II
25	Recruiting	Primary Myelofibrosis	Drug: Pomalidomide Other: Placebo Proportion of subjects achieving RBC-transfusion-independence	NCT01178281	Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence	Phase III

* Brief explanation of Study Phases: Phase I trials study safety and side effects. Phase II trials study effectiveness and safety. Phase III trials further study effectiveness and side effects, and compare with existing treatments. Phase IV trials study a treatment after it has entered the market. Phases I, II and III involve progressively larger groups of people. For further explanation, see clinicaltrials.gov. [ Back To Top ]

3. Trials for Essential Thrombocythemia

Line No.	Recruiting Status	Condition(s) to be Studied	Drugs tested and primary outcomes	clinicaltrials.gov ref. # - click it for more information	Study title	Study Phase*
1	Recruiting	High Risk Polycythemia Vera High Risk Essential Thrombocythemia	Drug: PEGASYS Drug: Hydroxyurea Drug: Aspirin To compare hematologic response rates in patients randomized to treatment with Pegylated Interferon Alfa-2a vs Hydroxyurea in two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET).	NCT01259856	Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)	Phase III
2	Not yet recruiting	High Risk Polycythemia Vera High Risk Essential Thrombocythemia	Drug: PEGASYS Drug: Aspirin Evaluate the ability of Pegylated Interferon Alfa-2a to achieve Complete Response or Partial Response in patients with (1) high risk polycythemia vera or (2) high risk essential thrombocythemia or (3) splanchnic vein thrombosis	NCT01259817	Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)	Phase II
3	Recruiting	Essential Thrombocythaemia	Drug: Anagrelide retard Drug: Placebo Time to 1st clinically significant ET related event	NCT01230775	Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia	Phase III
4	Not yet recruiting	Primary Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis	Drug: AB0024 Using the International Working Group criteria, determine the number of patients that respond to AB0024 ater 2 cycles of treatment. If no patients respond after 2 cycles, the study will be stopped.	NCT01242709	Study in Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis	Phase II
5	Recruiting	Essential Thrombocythaemia	Drug: SPD422 (anagrelide hydrochloride) Safety of long-term use of SPD422 Safety will be determined by the changes from study baseline in clinical laboratory evaluations, vital signs, and electrocardiograms (ECGs) recorded as an AE if clinically relevant.	NCT01467661	Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia	Phase III
6	Available	Myelofibrosis Post Polycythemia Myelofibrosis Post-essential Thrombocythemia Myelofibrosis	Drug: INC424	NCT01493414	INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis	Expanded Access
7	Not yet recruiting	Polycythemia Vera Essential Thrombocythemia Primary Myelofibrosis	Drug: PegIntron Drug: Pegasys Drug: Hydrea Drug: Multiferon molecular response (changes from baseline) Molecular responses (JAK V617F allele burden) are assesed by qPCR according to the ELN guidelines.	NCT01387763	A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms	Phase III
8	Recruiting	Myelofibrosis Primary Myelofibrosis Post-polycythemia Vera Related Myelofibrosis Post-essential Thrombocythemia Related Myelofibrosis	Biological: monoclonal antibody to TGF-beta To assess the safety and tolerability of GC1008 in patients with primary myelofibrosis (PMF) or post-polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF).	NCT01291784	Anti-TGF-beta Therapy in Patients With Myelofibrosis	Phase I
10	Recruiting	Primary Myelofibrosis (MF) Post-Polycythemia Vera (PV) MF Post-Essential Thrombocythemia (ET) MF	Drug: Ruxolitinib Efficacy by reduction in spleen volume	NCT01392443	Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF	Phase II
11	Recruiting	Primary Myelofibrosis Post-Polycythemia Vera Post-Essential Thrombocythemia Myelofibrosis	Drug: CYT387 To determine the safety of CYT387 by characterization and relationship of adverse events, affects on vital signs and laboratory parameters, and QTc intervals as measured by electrocardiogram (ECG) To determine maximum tolerated dose of CYT387 by characterization of Dose Limiting Toxicities To confirm the half-life of CYT387 by pharmacokinetic analyses To determine the efficacy of CYT387 by evaluation of spleen and liver size, disease related constitutional symptoms, transfusion dependence and anemia response.	NCT01423058	Safety Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis	Phase I Phase II
12	Recruiting	Idiopathic Myelofibrosis Post Essential Thrombocythemia Myelofibrosis Post Polycythemia-Vera Myelofibrosis	Drug: panobinostat, ruxolitinib Percentage of Responders as measured by a change in spleen length of at least 50% reduction as determined by manual palpation; from Baseline (Cycle 1 Day 1) to Week 12, and maintained until Week 24	NCT01433445	Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis	Phase I
13	Recruiting	Primary Myelofibrosis Post Essential Thrombocythemia-myelofibrosis Post Polycythemia Vera-myelofibrosis	Drug: Ruxolitinib (INCB018424) Measure spleen volume changes in patients with PMF, PPV-MF and PET-MF	NCT01348490	Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis	Phase II
14	Recruiting	Thrombocythemia Myeloproliferative Disorder	Drug: Hydroxyurea Drug: Aspirin Does hydroxyurea reduce thrombosis and major haemorrhage when added to aspirin? What is the effect of the treatment modalities on quality of life?	NCT00175838	Primary Thrombocythaemia 1 Trial	_
15	Recruiting	Thrombocythemia, Hemorrhagic	Drug: Anagrelide Drug: Hydroxyurea Cardiovascular safety as assessed by echocardiography over 3 years.	NCT00202644	A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients	Phase IV
16	Recruiting	Primary Myelofibrosis Post-Polycythemia Vera Related Myelofibrosis Post-Essential Thrombocythemia Related Myelofibrosis	Drug: LBH589 To assess the safety and tolerability of oral LBH589 in patients with PMF, post-PV/ET MF Phase I Evaluation of treatment response by International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Phase II	NCT01298934	LBH589 (Panobinostat) for the Treatment of Myelofibrosis	Phase I Phase II
17	Recruiting	Hematopoietic Neoplasm	Drug: SAR302503 Polycythemia vera: Proportion of patients with absence of phlebotomy and hematocrit below 45% for a minimum of 3 months after completion of 8 cycles of therapy Essential thrombocythemia: Proportion of patients with a platelet count ≤ 400 x 10x9/L for a minimum of 3 months after completion of 8 cycles of therapy	NCT01420783	Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia	Phase II
18	Recruiting	Polycythemia Vera Thrombocythemia	Drug: CC-4047 Number of Patients with Response	NCT00946270	Pomalidomide for Myelofibrosis Patients	Phase II
19	Recruiting	Primary Myelofibrosis Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase	Drug: Ruxolitinib Mean % change in spleen volume as measured by MRI	NCT01445769	Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis	Phase II
20	Recruiting	Hematopoietic Neoplasm	Drug: SAR302503 Drug: Placebo Response Rate (RR), defined as the proportion of patients who have a ≥35% reduction in volume of spleen size at the end of Cycle 6, and confirmed 4 weeks thereafter	NCT01437787	Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis	Phase III
21	Recruiting	Myelofibrosis	Drug: GS-6624 (AB0024) at 700 mg Drug: GS-6624 (AB0024) at 200 mg Using the International Working Group criteria, determine the number of patients that respond to AB0024 ater 2 cycles of treatment •To evaluate the efficacy of AB0024 as therapy for Primary Myelofibrosis (PMF) and Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (post-PV MF or post-ET MF). Best overall response will be categorized according to the International Working Group (IWG) Criteria. Efficacy will be measured by Rate of clinical response as defined by IWG criteria. Stable disease with improvement in bone marrow fibrosis score, clinical improvement, partial remission, or complete remission will be considered a response.	NCT01369498	A Phase 2 Study to Evaluate the Efficacy and Safety of AB0024 in Adults With Myelofibrosis	Phase II
23	Recruiting	Hematopoietic Neoplasm	Drug: SAR302503 The percent change in spleen volume based on MRI at the end of Cycle 3 relative to baseline	NCT01420770	Phase 2 Study of SAR302503 in Patients With Myelofibrosis	Phase II
24	Recruiting	Myelofibrosis	Drug: Ruxolitinib To establish the MSSD of ruxolitinib in patients with MF and baseline platelet counts < 100,000 as measured through blood sampling.	NCT01317875	Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)	Phase I
25	Recruiting	Myelofibrosis	Drug: Busulfan Drug: Fludarabine Drug: Thymoglobulin (ATG) Rate of Non-Relapse Mortality (NRM)	NCT00475020	Allogeneic Stem Cell Transplantation for Myelofibrosis	Phase II
26	Recruiting	Myeloproliferative Diseases	Drug: Ruxolitinib Drug: Lenalidomide Drug: Prednisone Objective Response Rate Objective response rate equals Complete and Partial Response, and Clinical Improvement as defined by International Working Group for Myelofibrosis Research and Treatment (IWG-MRT).	NCT01375140	Ruxolitinib and Lenalidomide for Patients With Myelofibrosis	Phase II
27	Recruiting	Primary Myelofibrosis	Drug: Pomalidomide Other: Placebo Proportion of subjects achieving RBC-transfusion-independence	NCT01178281	Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence	Phase III
28	Recruiting	Primary Myelofibrosis Fibrosis, Bone Marrow	Drug: oral daily dosing To determine the overall response rate of IPI-926, defined as clinical improvement (CI); partial remission (PR); and complete remission (CR), according to the International working group (IWG) criteria in patients with Myelofibrosis	NCT01371617	A Phase 2 Study With IPI-926 in Patients With Myelofibrosis	Phase II
29	Recruiting	Myeloproliferative Disorders Thrombocythemia, Essential Polycythemia Vera Primary Myelofibrosis	Drug: LY2784544 Determination of a recommended Phase 2 dosing regimen Number of participants with clinical significant effects	NCT01134120	A Study in Myeloproliferative Disorders	Phase I

* Brief explanation of Study Phases: Phase I trials study safety and side effects. Phase II trials study effectiveness and safety. Phase III trials further study effectiveness and side effects, and compare with existing treatments. Phase IV trials study a treatment after it has entered the market. Phases I, II and III involve progressively larger groups of people. For further explanation, see clinicaltrials.gov. [ Back To Top ]

4. Trials for other MPNs

Line No.	Recruiting Status	Condition(s) to be Studied	Drugs tested and primary outcomes	clinicaltrials.gov ref. # - click it for more information	Study title	Study Phase*
1	Recruiting	Myelofibrosis	Drug: Busulfan Drug: Fludarabine Drug: Thymoglobulin (ATG) Rate of Non-Relapse Mortality (NRM)	NCT00475020	Allogeneic Stem Cell Transplantation for Myelofibrosis	Phase II
2	Recruiting	Primary Myelofibrosis	Drug: Pomalidomide Other: Placebo Proportion of subjects achieving RBC-transfusion-independence	NCT01178281	Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence	Phase III
3	Not yet recruiting	Primary Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis	Drug: AB0024 Using the International Working Group criteria, determine the number of patients that respond to AB0024 ater 2 cycles of treatment. If no patients respond after 2 cycles, the study will be stopped.	NCT01242709	Study in Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis	Phase II
4	Recruiting	Myelofibrosis Primary Myelofibrosis Post-polycythemia Vera Related Myelofibrosis Post-essential Thrombocythemia Related Myelofibrosis	Biological: monoclonal antibody to TGF-beta To assess the safety and tolerability of GC1008 in patients with primary myelofibrosis (PMF) or post-polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF).	NCT01291784	Anti-TGF-beta Therapy in Patients With Myelofibrosis	Phase I
5	Not yet recruiting	Polycythemia Vera Essential Thrombocythemia Primary Myelofibrosis	Drug: PegIntron Drug: Pegasys Drug: Hydrea Drug: Multiferon molecular response (changes from baseline) Molecular responses (JAK V617F allele burden) are assesed by qPCR according to the ELN guidelines.	NCT01387763	A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms	Phase III
6	Available	Myelofibrosis Post Polycythemia Myelofibrosis Post-essential Thrombocythemia Myelofibrosis	Drug: INC424	NCT01493414	INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis	Expanded Access
7	Recruiting	Myelofibrosis	Drug: GS-6624 (AB0024) at 700 mg Drug: GS-6624 (AB0024) at 200 mg Using the International Working Group criteria, determine the number of patients that respond to AB0024 ater 2 cycles of treatment •To evaluate the efficacy of AB0024 as therapy for Primary Myelofibrosis (PMF) and Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (post-PV MF or post-ET MF). Best overall response will be categorized according to the International Working Group (IWG) Criteria. Efficacy will be measured by Rate of clinical response as defined by IWG criteria. Stable disease with improvement in bone marrow fibrosis score, clinical improvement, partial remission, or complete remission will be considered a response.	NCT01369498	A Phase 2 Study to Evaluate the Efficacy and Safety of AB0024 in Adults With Myelofibrosis	Phase II
8	Recruiting	Primary Myelofibrosis	Drug: Dose Escalating Arsenic Trioxide plus ascorbic Acid To determine the safety and maximum tolerated dose of oral arsenic trioxide with or without ascorbic acid is subjects with JAK2-positive myelofibrosis	NCT01014546	Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults With Myelofibrosis	Phase I
9	Recruiting	Primary Myelofibrosis Fibrosis, Bone Marrow	Drug: oral daily dosing To determine the overall response rate of IPI-926, defined as clinical improvement (CI); partial remission (PR); and complete remission (CR), according to the International working group (IWG) criteria in patients with Myelofibrosis	NCT01371617	A Phase 2 Study With IPI-926 in Patients With Myelofibrosis	Phase II
10	Recruiting	Primary Myelofibrosis (MF) Post-Polycythemia Vera (PV) MF Post-Essential Thrombocythemia (ET) MF	Drug: Ruxolitinib Efficacy by reduction in spleen volume	NCT01392443	Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF	Phase II
11	Recruiting	Myeloproliferative Diseases	Drug: Ruxolitinib Drug: Lenalidomide Drug: Prednisone Objective Response Rate Objective response rate equals Complete and Partial Response, and Clinical Improvement as defined by International Working Group for Myelofibrosis Research and Treatment (IWG-MRT).	NCT01375140	Ruxolitinib and Lenalidomide for Patients With Myelofibrosis	Phase II
12	Recruiting	Hematopoietic Neoplasm	Drug: SAR302503 Drug: Placebo Response Rate (RR), defined as the proportion of patients who have a ≥35% reduction in volume of spleen size at the end of Cycle 6, and confirmed 4 weeks thereafter	NCT01437787	Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis	Phase III
13	Recruiting	Primary Myelofibrosis Post Essential Thrombocythemia-myelofibrosis Post Polycythemia Vera-myelofibrosis	Drug: Ruxolitinib (INCB018424) Measure spleen volume changes in patients with PMF, PPV-MF and PET-MF	NCT01348490	Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis	Phase II
14	Recruiting	Idiopathic Myelofibrosis Post Essential Thrombocythemia Myelofibrosis Post Polycythemia-Vera Myelofibrosis	Drug: panobinostat, ruxolitinib Percentage of Responders as measured by a change in spleen length of at least 50% reduction as determined by manual palpation; from Baseline (Cycle 1 Day 1) to Week 12, and maintained until Week 24	NCT01433445	Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis	Phase I
15	Recruiting	Primary Myelofibrosis Post-Polycythemia Vera Related Myelofibrosis Post-Essential Thrombocythemia Related Myelofibrosis	Drug: LBH589 To assess the safety and tolerability of oral LBH589 in patients with PMF, post-PV/ET MF Phase I Evaluation of treatment response by International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Phase II	NCT01298934	LBH589 (Panobinostat) for the Treatment of Myelofibrosis	Phase I Phase II
16	Recruiting	Primary Myelofibrosis Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase	Drug: Ruxolitinib Mean % change in spleen volume as measured by MRI	NCT01445769	Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis	Phase II
17	Recruiting	Primary Myelofibrosis Post-Polycythemia Vera Post-Essential Thrombocythemia Myelofibrosis	Drug: CYT387 To determine the safety of CYT387 by characterization and relationship of adverse events, affects on vital signs and laboratory parameters, and QTc intervals as measured by electrocardiogram (ECG) To determine maximum tolerated dose of CYT387 by characterization of Dose Limiting Toxicities To confirm the half-life of CYT387 by pharmacokinetic analyses To determine the efficacy of CYT387 by evaluation of spleen and liver size, disease related constitutional symptoms, transfusion dependence and anemia response.	NCT01423058	Safety Study Evaluating Twice-Daily Administration of CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis	Phase I Phase II
18	Recruiting	Myeloproliferative Disorders Thrombocythemia, Essential Polycythemia Vera Primary Myelofibrosis	Drug: LY2784544 Determination of a recommended Phase 2 dosing regimen Number of participants with clinical significant effects	NCT01134120	A Study in Myeloproliferative Disorders	Phase I
19	Recruiting	Myelodysplastic Syndrome (MDS) Aplastic Anaemia (AA) Myelofibrosis (MF) Thalassemia Intermedia	Drug: Chinese herbal concoction twice a day for 6 months Number of Participants with Adverse Events as a Measure of Safety and Tolerability The following parameters will be monitored serially symptoms : ie reflection of any subjective symptoms that may be due to the treatment Serial biochemistry ( urea, electrolyte, creatinine, liver function test ) will be done at baseline, one week into the study and then every 7-8 weekly till end of the 6 months. This will monitor for any organ toxicity	NCT01224496	Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders	Phase I Phase II
20	Recruiting	Polycythemia Vera Thrombocythemia	Drug: CC-4047 Number of Patients with Response	NCT00946270	Pomalidomide for Myelofibrosis Patients	Phase II
21	Recruiting	Hematopoietic Neoplasm	Drug: SAR302503 The percent change in spleen volume based on MRI at the end of Cycle 3 relative to baseline	NCT01420770	Phase 2 Study of SAR302503 in Patients With Myelofibrosis	Phase II
22	Recruiting	Myelofibrosis	Drug: Ruxolitinib To establish the MSSD of ruxolitinib in patients with MF and baseline platelet counts < 100,000 as measured through blood sampling.	NCT01317875	Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)	Phase I
24	Recruiting	Cancer	Drug: BMS-911543 Safety assessed by medical review of adverse events and results of vital signs, Electrocardiograms (ECGs), physical examinations, and lab tests and evaluated using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 Total number of subjects with the Investigator reported Complete Remission (CR), Partial remission (PR), or Clinical improvement (CI) divided by the total number of treated subjects	NCT01236352	Multiple Ascending Dose of BMS-911543	Phase I Phase II

* Brief explanation of Study Phases: Phase I trials study safety and side effects. Phase II trials study effectiveness and safety. Phase III trials further study effectiveness and side effects, and compare with existing treatments. Phase IV trials study a treatment after it has entered the market. Phases I, II and III involve progressively larger groups of people. For further explanation, see clinicaltrials.gov. [ Back To Top ]